NCT05590377

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (iinnovate-3)



Sponsor: Takeda

Purpose of this study?

 

The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.


 

Key Inclusion Criteria:

 

  1. Documented multiple myeloma (MM) diagnosis per IMWG criteria.
  2. Measurable disease, defined as at least 1 of the following:
  3. Serum M protein ≥0.5 grams per deciliter [g/dL] (≥5 g/L) on serum protein electrophoresis (SPEP).
  4. Urine M protein ≥200 mg/24 hours on urine protein electrophoresis (UPEP).
  5. Serum free light chain (FLC) assay with involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal.
  6. For participants in the Phase 1 Dose Escalation only:
  7. Must have received at least 3 prior lines of therapy, including at least 1 proteosome inhibitor (PI), 1 immunomodulatory imide drug (IMiD), and 1 anti-CD38 monoclonal antibody (mAb) drug; or who are triple refractory to a PI, an IMiD, and an anti-CD38 mAb drug, regardless of the number of prior line(s) or therapy.
  8. For participants in Phase 2a Dose Finding only:
  9. Received 1 to 3 prior line(s) of antimyeloma therapy.
  10. Must be refractory to prior lenalidomide treatment.
  11. Participants must be sensitive (nonrefractory) or naïve to prior anti-CD38 mAb treatment.
  12. Documented progressive disease on or after the last regimen.
  13. Participants must have PR or better to at least 1 line of prior therapy.
  14. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at screening.

 

 

Key Exclusion Criteria:

 

  1. Prior exposure to modakafusp alfa.
  2. Participant has polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, solitary plasmacytoma, amyloidosis, Waldenström macroglobulinemia, plasma cell leukemia, or lymphoplasmacytic lymphoma.
  3. Participant has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE, Version 5 Grade ≤1 or baseline, except for alopecia.
  4. Previous allogeneic stem cell transplant at any time or autologous stem cell transplant (ASCT) within 12 weeks of planned start of dosing.
  5. Seropositive for hepatitis B, or known history of seropositivity for hepatitis C or of seropositivity for human immunodeficiency virus (HIV).
  6. Participant has congestive heart failure (New York Heart Association Grade ≥II), cardiac myopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension.
  7. Participant has QT interval corrected by the Fridericia method >480 milliseconds [msec] (Grade ≥2).
  8. Participant has a chronic condition that will require the chronic use of systemic corticosteroids >10 milligrams per day (mg/d) of prednisone or equivalent on top of any required corticosteroids for multiple myeloma (MM).

 

Primary Outcome Measures:

 

  1. Phase 1: Number of Participants with Dose Limiting Toxicities (DLT) [ Time Frame: Cycle 1 (cycle length=28 days) ]


  1. DLT will be defined as any of the TEAEs that occur during Cycle 1 and are considered by the investigator to be at least possibly related to modakafusp alfa. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
  2. Phase 1: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Per Severity [ Time Frame: Up to 60 months ]
  3. An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Severity grades for TEAEs will be evaluated as per the NCI CTCAE Version 5.0.
  4. Phase 2a: Overall Response Rate (ORR) [ Time Frame: Up to 60 months ]
  5. ORR is defined as the percentage of participants who achieve a confirmed partial response (PR) or better during the study in the safety population. ORR will be assessed by the investigator per International Myeloma Working Group (IMWG) criteria.

 

Secondary Outcome Measures:

 

  1. Phase 1: Cmax: Single-Dose Maximum Observed Serum Concentration for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  2. Phase 1: Tmax: Time to First Occurrence of Maximum Serum Concentration (Cmax) for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  3. Phase 1: AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  4. Phase 1: AUClast: Area Under the Serum Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  5. Phase 1: Apparent Serum Terminal Disposition Rate Constant for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  6. Phase 1: Apparent Serum Terminal Disposition Phase Half-life for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  7. Phase 1: Total Clearance After Intravenous Administration for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  8. Phase 1: Volume of Distribution at Steady State After Intravenous Administration for Modakafusp Alfa [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  9. Phase 1: Cmax: Single-Dose Maximum Observed Serum Concentration for Daratumumab [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  10. Phase 1: Tmax: Time to First Occurrence of Maximum Serum Concentration (Cmax) for Daratumumab [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  11. Phase 1: Ctrough: Single-Dose and Multiple-dose Observed Concentration at the End of a Dosing Interval for Daratumumab [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  12. Phase 1: AUC∞: Area Under the Serum Concentration-time Curve from Time 0 to Infinity for Daratumumab [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  13. Phase 1: AUClast: Area Under the Serum Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration for Daratumumab [ Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days) ]
  14. Phase 1: Overall Response Rate (ORR) [ Time Frame: Up to 60 months ] ORR is defined as the percentage of participants who achieved a confirmed PR or better during the study in the safety population. ORR will be assessed by the investigator per IMWG criteria.
  15. Phase 1 and Phase 2a: Duration of Response (DOR) [ Time Frame: Up to 60 months ] DOR is defined as the time from the date of first documentation of a confirmed PR or better to the date of first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. DOR will be calculated for confirmed responders only (PR or better). DOR will be assessed by the investigator as per IMWG criteria.
  16. Phase 1 and Phase 2a: Progression Free Survival (PFS) [ Time Frame: up to 60 months ] PFS is defined as the time from the date of the first dose administration of any study drug to the first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. PFS will be assessed by the investigator as per IMWG criteria.
  17. Phase 1 and Phase 2a: Overall Survival (OS) [ Time Frame: Up to 60 months ] OS is defined as the time from the date of the first dose administration of any study drug to the documentation of death due to any cause. OS will be assessed by the investigator as per IMWG criteria.
  18. Phase 1 and Phase 2a: Number of Participants With Anti-drug Antibodies [ Time Frame: Up to 60 months ]
  19. Phase 1 and Phase 2a: Titer of Anti-drug Antibodies [ Time Frame: Up to 60 months ]
  20. Phase 1 and Phase 2a: Number of Participants With Neutralizing Antibodies (NAb) Against Study Drug [ Time Frame: Up to 60 months ]
  21. Phase 1 and Phase 2a: Rate of Measurable [Minimal] Residual Disease Negative (MRD[-]) Complete Response (CR) [ Time Frame: Up to 60 months ] MRD[-] CR rate is defined as the percentage of participants who achieve confirmed CR assessed by the investigator and MRD[-] status using a threshold of 10^-5. The analysis will be based on the response-evaluable population.
  22. Phase 1 and Phase 2a: Duration of Measurable [Minimal] Residual Disease (MRD) Negativity [ Time Frame: Up to 60 months ] Duration of MRD negativity for participants achieving MRD negativity is defined as the time from the date of first documentation of MRD negativity to the first documentation of MRD positivity or confirmed progressive disease, whichever occurs first. It will be calculated for participants achieving MRD negativity only.
  23. Phase 2a: Clinical Benefit Rate (CBR) [ Time Frame: Up to 60 months ] CBR is defined as the percentage of participants who had a confirmed response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response based on investigators' disease assessment per IMWG criteria.
  24. Phase 2a: Duration of Clinical Benefit (DCB) [ Time Frame: Up to 60 months ] DCB is defined as the time from the date of first documentation of a minimal response or better to the date of first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. DCB will be calculated for only participants who achieved a minimal response or better. DCB will be assessed by the investigator as per IMWG criteria.
  25. Phase 2a: Disease Control Rate (DCR) [ Time Frame: Up to 60 months ] DCR is defined as the percentage of participants with a confirmed response of sCR, CR, VGPR, PR, minimal response, or stable disease (SD) based on investigators' disease assessment per IMWG criteria.
  26. Phase 2a: Duration of Disease Control [ Time Frame: Up to 60 months ] Duration of disease control is defined as the time from date of first documentation of SD or better to the date of first documentation of confirmed progressive disease or death due to any cause. Duration of disease control will be calculated for only patients who achieved SD or better. It will be assessed by the investigator per IMWG criteria.
  27. Phase 2a: Time to Progression (TTP) [ Time Frame: Up to 60 months ] TTP is defined as the time from the date of randomization to the first documentation of confirmed progressive disease as defined by IMWG criteria, assessed by the investigator. Participants without documentation of confirmed progression will be censored at the date of last adequate disease assessment. The analysis will be based on the intent-to-treat (ITT) population.
  28. Phase 2a: Time to Response (TTR) [ Time Frame: Up to 60 months ] TTR is defined as time from the date of first dose administration of any study drug to the date of the first documentation of a confirmed PR or better. TTR will be calculated for responders only. TTR will be assessed by the investigator per IMWG criteria.
  29. Phase 2a: Time to Next Treatment (TTNT) [ Time Frame: Up to 60 months ]TTNT is defined as the time from the date of first dose administration of any study drug to the date of the first dose initiation of the next line of anticancer therapy for any reason or death from any cause, whichever comes first. Participants who have not started the next-line therapy will be censored at the date last known to be alive before subsequent anticancer therapy.
  30. Phase 2a: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Per Severity [ Time Frame: Up to 60 months ] An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Severity grades for TEAEs will be evaluated as per the NCI CTCAE Version 5.0.


 

Study Locations in Europe: Czech Republic, France, Germany, Hungary, Spain.

 

Estimated Study Completion Date: March 4, 2025

 

Further information on clinicaltrial.gov - trial number NCT05590377






Share by: